Gilead Sciences, Inc.

Netsuite Inc.

Kronos Bio, Inc.

Peter C Fung

Olga Viktorovna Lapina

Patricia Andres

Duong D Tran

Chiajen Lai

Katie Ann Keaton

Henry G Morrison

Henry Morrison

Jeffrey N Hemenway

Jing Teng

Stephen Clode

Dominika Pcion

Anna Michelle Wagner

Nolan Griggs

Johann Chan

Sean Timothy Neville

Derek M Dalton

Matthew M Logan

Dustin Bringley

Hui-Wen Shih

Bryan J Reynolds

Xiaozheng (Michael) Ye

Andrew Owen Vincent

Jeremy John Blanchard

Dennis Paul Shak

Brian Yarmuch

Iva Trantcheva

Craig Stewart

Pierre Giguere

Brian Purville

Truman (Clyde) Adley, Jr

Jeffrey Jones

Christopher Craxton

Sean T Neville

Anna M Wagner

Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized: Also provided are processes of making the solid forms and methods of use thereof.

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.

Solid forms of FXR agonists

Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized:  Also provided are processes of making the solid forms and methods of use thereof.

Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors

Systems and methods of processing business related data arising from multiple revenue sources (e.g., sales, subscriptions, professional services, vendors, etc.). In some embodiments, the inventive system and methods enable a more flexible and efficient approach to identifying revenue source events (mediation), pricing those events (typically as part of a rating process), and subsequently leveraging those 'ratable events' in the billing and revenue recognition subsystems according to configurable rules and schedules. Data regarding those charges or other aspects of a ratable event may then be used and processed by multiple sub-systems that are part of operating a business; such sub-systems may include one or more of ERP, CRM, HCM, financial, accounting, taxation, or other business-related system or function.

System and method for implementing unified billing and unified rating operations

Methods, systems, and apparatuses for improving the handling and interaction of charge events in a business using services of a multi-tenant computing platform, such as accounting, CRM, ERP, and the like. Embodiments are directed to implementing and using a charge record to enable efficient use of charges originating from multiple sources to generate reports and forecasts for multiple other services and/or recipients. In one embodiment, the charge record defines a single-source of data which enables maintaining critical business information in synchronization through a single repository of data. One aspect is to define a single abstraction, the charge record, which all sources can create. Thus, instead of multiple relationship between multiple sources and multiple processes, a charge record provides a single data point for a charge such that charges sources and processes that utilize data from the charge sources may interact using a single type of data record.

System and method for implementing charge centric billing

Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Crystalline forms of an antiviral compound

Growing community of inventors

San Mateo, CA, United States of America

Peter C Fung